Pharma Mar

Pharma Mar PHMMF Stock

$72.54   0.000000%
Add to favorites
Market Cap
$1.25B
LOW - HIGH [24H]
$75.05 - $75.05
VOLUME [24H]
$100.00
P/E Ratio
15.90
Earnings per share
$4.56
ISIN
ES0169501022
Price   Prediction

Pharma Mar Price Chart

Sorry, that's all we've gotfor now...

Pharma Mar (PHMMF) stock price today is 72.54 USD on OTC Markets OTCPK (0% on the day). Updated .

Pharma Mar PHMMF Financial and Trading Overview

Pharma Mar stock price 72.54 USD
Previous Close 72.54 USD
Open 75.05 USD
Bid 69.77 USD x 30000
Ask 72.08 USD x 30000
Day's Range 75.05 - 75.05 USD
52 Week Range 70.7 - 106.48 USD
Volume 100 USD
Avg. Volume 23 USD
Market Cap 1.25B USD
Beta (5Y Monthly) 0.435
PE Ratio (TTM) 15.907895
EPS (TTM) 4.56 USD
Forward Dividend & Yield 1.14 (1.58%)
Ex-Dividend Date July 8, 2026
1y Target Est N/A

PHMMF Valuation Measures

Enterprise Value 1.15B USD
Trailing P/E 15.907895
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 5.271759
Price/Book (mrq) 4.723187
Enterprise Value/Revenue 4.85
Enterprise Value/EBITDA 20.358

Trading Information

Pharma Mar Stock Price History

Beta (5Y Monthly) 0.435
52-Week Change -16.0027%
S&P500 52-Week Change 10.51%
52 Week High 106.48 USD
52 Week Low 70.7 USD
50-Day Moving Average 88.59 USD
200-Day Moving Average 92.49 USD

PHMMF Share Statistics

Avg. Volume (3 month) 23 USD
Avg. Daily Volume (10-Days) 40 USD
Shares Outstanding 17.25M
Float 13.4M
Short Ratio N/A
% Held by Insiders 21.88%
% Held by Institutions 11.12%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield 114.99%
Payout Ratio 0.2546
Last Split Factor 1:12

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 28.79%
Operating Margin (ttm) 21.26%
Gross Margin 93.32%
EBITDA Margin 23.82%

Management Effectiveness

Return on Assets (ttm) 8.41%
Return on Equity (ttm) 31.46%

Income Statement

Revenue (ttm) 237.4M USD
Revenue Per Share (ttm) 13.69 USD
Quarterly Revenue Growth (yoy) 52.60%
Gross Profit (ttm) 221.56M USD
EBITDA 56.55M USD
Net Income Avi to Common (ttm) 68.37M USD
Diluted EPS (ttm) 4.56
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 176.29M USD
Total Cash Per Share (mrq) 10.17 USD
Total Debt (mrq) 70.07M USD
Total Debt/Equity (mrq) 29.56 USD
Current Ratio (mrq) 2.357
Book Value Per Share (mrq) 15.358274

Cash Flow Statement

Operating Cash Flow (ttm) 52.8M USD
Levered Free Cash Flow (ttm) 20.27M USD

Profile of Pharma Mar

Country United States
State N/A
City Madrid
Address Avenida de los Reyes, 1
ZIP 28770
Phone 34 91 846 60 00
Website https://www.pharmamar.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 505

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma. It also develops LAGOON, which is in Phase III clinical trial for the treatment of small cell lung cancer; SaLuDo, which is in Phase III trial to treat patients with metastatic leiomyosarcoma; as well as PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Q&A For Pharma Mar Stock

What is a current PHMMF stock price?

Pharma Mar PHMMF stock price today per share is 72.54 USD.

How to purchase Pharma Mar stock?

You can buy PHMMF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Pharma Mar?

The stock symbol or ticker of Pharma Mar is PHMMF.

Which industry does the Pharma Mar company belong to?

The Pharma Mar industry is Biotechnology.

How many shares does Pharma Mar have in circulation?

The max supply of Pharma Mar shares is 17.25M.

What is Pharma Mar Price to Earnings Ratio (PE Ratio)?

Pharma Mar PE Ratio is 15.90789500 now.

What was Pharma Mar earnings per share over the trailing 12 months (TTM)?

Pharma Mar EPS is 4.56 USD over the trailing 12 months.

Which sector does the Pharma Mar company belong to?

The Pharma Mar sector is Healthcare.

$2.17T
Total marketcap
$71.3B
Total volume
BTC 58.00%   •   ETH 9.96%
Dominance
Select currency